

# Phytotherapeutic Interventions in Osteochondral Regeneration: A Critical Analysis of Efficacy, Molecular Mechanisms, and Geriatric Safety Profiles

## 1. Introduction and Scope of Inquiry

The management of osteoarthritis (OA) and critical bone defects remains one of the most pervasive challenges in modern geriatric medicine. Characterized by the progressive degradation of articular cartilage, subchondral bone sclerosis, and synovial inflammation, OA represents a failure of the joint's organ-level homeostasis. Current pharmacotherapeutic strategies, dominated by non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, act primarily as palliative measures. They successfully mitigate pain and inflammation but fail to arrest the structural progression of the disease or induce genuine tissue regeneration. In some instances, chronic use of these agents may paradoxically accelerate cartilage catabolism or precipitate systemic toxicity, including gastrointestinal hemorrhage and renal impairment.

Consequently, the scientific community has increasingly pivoted toward ethnopharmacology, seeking bioactive compounds capable of disease-modifying osteoarthritis drug (DMOAD) activity. This report provides an exhaustive, expert-level evaluation of six specific herbal interventions that have recently emerged in the scientific literature: **Peedanil Gold**, **Osteoking**, **Leucas aspera**, **Albizia procera**, **Caryota mitis**, and the **Maxing Yigan Formula**.

The objective of this analysis is threefold. First, it rigorously validates the regenerative claims associated with these formulations by synthesizing primary data from rat models (MIA-induced OA, adjuvant-induced arthritis) and in vitro chondrocyte assays. Particular attention is paid to advanced molecular mechanisms, including the ZBP1-STAT1-PKR-MLKL necroptosis axis and the modulation of autophagy via collagen scaffolds. Second, it scrutinizes the methodological robustness of these studies, specifically challenging the histological classification of "complete regeneration" through the lens of polarized light microscopy and collagen typing. Third, recognizing that the primary consumer demographic for these agents is the elderly population, a substantial portion of this report is dedicated to a high-granularity toxicological analysis. We map the active phytochemical constituents of these formulations against common geriatric pharmacotherapies—anticoagulants, antihypertensives, and antidiabetics—to construct a comprehensive safety profile that

highlights potential herb-drug interactions (HDIs) and adverse events.

---

## 2. Peedanil Gold: Biochemical and Radiological Validation in the MIA-Induced OA Model

Peedanil Gold (PN-G) is a proprietary herbo-mineral formulation developed by the Patanjali Research Institute, grounded in Ayurvedic principles but subjected to modern pharmacological validation. The formulation is a complex matrix containing *Boswellia serrata* (Shallaki), *Commiphora mukul* (Guggul), and *Curcuma longa* (Turmeric), among other constituents.<sup>1</sup> The validation of its efficacy relies heavily on the Monosodium Iodoacetate (MIA) induced model of osteoarthritis in Sprague-Dawley (SD) rats, a model selected for its ability to rapidly reproduce the histopathological and functional impairments observed in human OA, including chondrocyte apoptosis and subchondral bone necrosis.

### 2.1 Efficacy in Attenuating OA Pathology

The primary investigative work by Balkrishna et al. (2022) established a dose-dependent amelioration of osteoarthritic symptoms following oral administration of PN-G. The study utilized the **Kellgren-Lawrence (K-L) grading system**, a standard radiological classification used in clinical settings to assess the severity of OA. Radiographs of the rat knee joints in the MIA-control group typically display severe narrowing of the joint space, subchondral sclerosis, and the formation of osteophytes (bone spurs). In contrast, the PN-G treated groups demonstrated significantly lower K-L scores, indicative of preserved joint architecture and reduced osteophytic remodeling.<sup>1</sup>

Beyond structural preservation, the study quantified functional recovery using behavioral assays. MIA injection induces severe pain phenotypes, measurable as mechanical hyperalgesia and tactile allodynia. Treatment with PN-G effectively rescued the osteoarthritic rats from these pain states, restoring gait parameters to levels comparable to the healthy control group.<sup>1</sup> This analgesic effect is likely mediated by the synergistic action of boswellic acids and curcuminoids, which are potent inhibitors of the 5-lipoxygenase (5-LOX) and cyclooxygenase-2 (COX-2) pathways, respectively.

### 2.2 Modulation of Pro-Inflammatory Cytokines

The progression of OA is driven by a "cytokine storm" within the synovial microenvironment. The analysis of PN-G focused on two pivotal mediators: **Interleukin-6 (IL-6)** and **Interleukin-1 beta (IL-1 $\beta$ )**.

- **IL-1 $\beta$  suppression:** IL-1 $\beta$  is often termed the "gatekeeper" of cartilage degradation. It upregulates the expression of Matrix Metalloproteinases (MMPs), specifically MMP-13, which cleaves type II collagen, the structural backbone of hyaline cartilage. Furthermore,

IL-1 $\beta$  suppresses the synthesis of aggrecan, the proteoglycan responsible for the cartilage's compressive stiffness. The administration of PN-G resulted in a significant, dose-dependent reduction of serum IL-1 $\beta$  levels.<sup>1</sup> By suppressing this cytokine, PN-G likely shifts the chondrocyte phenotype from a catabolic state toward anabolic repair.

- **IL-6 Downregulation:** Similarly, IL-6 levels, which promote synovial hyperplasia and osteoclastogenesis (bone resorption), were markedly reduced. This systemic reduction in inflammatory load provides a biochemical rationale for the observed reduction in joint swelling and pain.<sup>1</sup>

## 2.3 Biomarker Analysis: Cartilage Oligomeric Matrix Protein (COMP)

To corroborate radiological findings with biochemical evidence of cartilage preservation, the researchers utilized **Cartilage Oligomeric Matrix Protein (COMP)** as a serum biomarker. COMP is a non-collagenous protein abundant in articular cartilage; its presence in the serum is a specific indicator of cartilage turnover and destruction. In the MIA-induced model, serum COMP levels are typically elevated, reflecting the rapid degradation of the matrix. The PN-G treated groups showed a significant reduction in serum COMP levels, effectively indistinguishable from the non-arthritic control group.<sup>1</sup> This serves as a robust proxy for "effective cartilage regeneration" or, more precisely, the arrest of cartilage degeneration.

## 2.4 Comparative Potency: PN-G vs. Indomethacin

A critical component of the study was the benchmarking of PN-G against **Indomethacin**, a potent non-selective NSAID often used as a positive control in arthritis research. The comparative analysis revealed that PN-G was "equally effective" to Indomethacin in alleviating osteoarthritic pain phenotypes and restoring knee joint morphology.<sup>1</sup>

This finding is clinically significant due to the toxicity profile of Indomethacin. Chronic use of Indomethacin is associated with a high risk of peptic ulceration, gastrointestinal bleeding, and nephrotoxicity. By achieving parity in efficacy without the associated gastric liability (a claim supported by the "cytosafe" concentrations noted in in-vitro assays <sup>1</sup>), PN-G presents a compelling alternative for long-term management, provided its herbo-mineral composition is devoid of heavy metal toxicity—a subject discussed extensively in Section 9.

## 2.5 Histopathological Assessment of Regeneration

The study authors explicitly claim "effective cartilage regeneration" based on histopathological evidence.<sup>1</sup> The methodology utilized **Safranin-O staining**, a cationic dye that binds stoichiometrically to the polyanionic glycosaminoglycans (GAGs) in cartilage. In OA, the loss of GAGs results in a loss of Safranin-O staining (loss of the "red zone").

- **Observations:** The PN-G treated groups exhibited a restoration of Safranin-O staining intensity, indicating the replenishment of the proteoglycan matrix.<sup>1</sup>
- **Limitations:** While this indicates matrix synthesis, the provided research snippets

suggest the use of brightfield microscopy (Nikon E100) rather than polarized light microscopy.<sup>1</sup> Consequently, while the matrix is replenished, confirming whether the regenerated tissue is organized **hyaline cartilage** (Type II collagen) or disorganized **fibrocartilage** (Type I collagen) remains a methodological gap.

---

### 3. Osteoking: Unraveling the ZBP1–STAT1–PKR–MLKL Necroptosis Axis

Osteoking (Henggu Gushangyu) is a Traditional Chinese Medicine (TCM) liquid formulation with a long history of use for femoral head necrosis and lumbar disc herniation. However, recent investigations published in *Chinese Medicine* (2024) have elevated the understanding of its mechanism from general "blood activation" to the specific inhibition of **necroptosis**, a regulated form of inflammatory cell death.

#### 3.1 The Biology of Necroptosis in Bone Defects

Unlike apoptosis, which is a clean, non-inflammatory cell death, necroptosis is lytic and pro-inflammatory. It releases Damage-Associated Molecular Patterns (DAMPs) into the microenvironment, perpetuating inflammation and inhibiting osteogenesis. This process is governed by the phosphorylation of **Mixed Lineage Kinase Domain-Like protein (MLKL)**, which translocates to the plasma membrane to form pores, causing cell rupture.

#### 3.2 The ZBP1–STAT1–PKR Regulatory Axis

The research by Zhang, Lin, et al. identified a novel upstream regulatory axis for necroptosis in bone defects: the **ZBP1–STAT1–PKR** pathway.<sup>5</sup>

- **ZBP1 (Z-DNA Binding Protein 1):** Normally a sensor for viral DNA, ZBP1 can be aberrantly activated by endogenous Z-form DNA or RNA produced during cellular stress in bone defects.
- **STAT1 and PKR:** Upregulated ZBP1 recruits and activates STAT1 (Signal Transducer and Activator of Transcription 1) and PKR (Protein Kinase R). This complex acts as the trigger for the canonical necroptosis machinery.
- **Osteoking's Intervention:** In bone defect rats, the expression of ZBP1, STAT1, and PKR is distinctly elevated. Osteoking treatment was shown to effectively reverse this upregulation. By suppressing the upstream ZBP1–STAT1–PKR axis, Osteoking prevents the downstream phosphorylation of **RIPK1** (Receptor-Interacting Protein Kinase 1) and **RIPK3**, thereby ultimately inhibiting the activation of MLKL and blocking the necroptotic cascade.<sup>5</sup>

#### 3.3 Cytokine Modulation as a Consequence of Necroptosis Inhibition

The lytic nature of necroptosis releases a specific profile of inflammatory cytokines. The study

identified TNF- $\alpha$ , IL-1 $\beta$ , and IL-6 as the "hallmark inflammatory cytokines for the end of necroptosis".<sup>5</sup>

- **Findings:** The elevated levels of these cytokines in the bone tissue supernatants of defect rats were significantly suppressed by Osteoking.<sup>8</sup> This reduction is not merely anti-inflammatory in the general sense; it is a direct readout of preserved cell membrane integrity due to MLKL inhibition. By preventing the necroptotic rupture of osteoblasts and chondrocytes, Osteoking maintains a viable cell population necessary for bridging critical-sized bone defects.

### 3.4 TGF- $\beta$ /Smad Signaling and Chondrocyte Metabolism

In addition to preventing cell death, Osteoking actively promotes anabolism via the **Transforming Growth Factor-beta (TGF- $\beta$ )** signaling pathway. Research utilizing the destabilization of the medial meniscus (DMM) mouse model demonstrated that Osteoking acts in a TGF- $\beta$ /Smad-dependent manner to protect articular cartilage.<sup>9</sup>

- **Rebalancing Metabolism:** Osteoarthritis is characterized by a shift from anabolism (matrix synthesis) to catabolism (matrix degradation). In the DMM model, the expression of TGF- $\beta$  receptor II (TGF $\beta$ RII) and phosphorylated Smad2 (pSmad2)—drivers of collagen synthesis—is suppressed. Conversely, MMP-13 expression is upregulated.
- **Therapeutic Restoration:** Osteoking treatment reversed this imbalance. It upregulated the expression of **Col2a1** (Type II collagen gene), TGF $\beta$ RII, and pSmad2, while simultaneously downregulating MMP-13.<sup>10</sup> This dual mechanism—blocking necroptosis to ensure cell survival and stimulating TGF- $\beta$  signaling to ensure matrix production—defines Osteoking's regenerative potential.

### 3.5 Formulation and Bioactive Constituents

The complexity of Osteoking's effects is attributable to its multi-herb composition. Ingredients include *Carthamus tinctorius* (Safflower), *Panax notoginseng*, *Eucommia ulmoides*, *Panax ginseng*, *Citrus reticulata*, *Astragalus hamosus*, *Schizophragma integrifolium*, *Trionyx sinensis* (Turtle shell), and, notably, **Datura metel**.<sup>12</sup>

- **Network Pharmacology:** Analyses have identified **kaempferol**, **quercetin**, and **beta-sitosterol** as key active ingredients binding to targets like TNF and IL-6.<sup>14</sup>
- **Datura metel:** The inclusion of this plant, a source of tropane alkaloids, is a critical safety consideration discussed in Section 9.

---

## 4. *Leucas aspera* and *Albizia procera*: Scrutinizing Claims of "Complete Regeneration"

The ethnopharmacological literature regarding *Leucas aspera* and *Albizia procera* contains

claims of "complete cartilage regeneration" in arthritic models. These assertions, if validated, would represent a paradigm shift in orthopedics, as adult articular cartilage possesses negligible intrinsic regenerative capacity.

#### 4.1 *Leucas aspera*: Antioxidant Restoration and Joint Architecture

Studies by Kripa et al. (2011) evaluated the ethanolic extract of *Leucas aspera* (EELA) in adjuvant-induced arthritic rats.<sup>15</sup> The pathogenesis of arthritis in this model is heavily driven by oxidative stress, where Reactive Oxygen Species (ROS) degrade the synovial membrane and cartilage matrix.

- **Antioxidant Profile:** EELA treatment significantly restored the levels of endogenous antioxidant enzymes: **Superoxide Dismutase (SOD)**, **Glutathione Peroxidase (GPx)**, and **Catalase (CAT)**, while raising levels of reduced glutathione (GSH).<sup>15</sup> The restoration of these enzymes to near-normal levels suggests that EELA acts as a potent free-radical scavenger, likely protecting chondrocytes from oxidative apoptosis.
- **Regenerative Findings:** The study reports that histopathological examination confirmed "complete cartilage regeneration and near normal joint" in high-dose groups.<sup>15</sup>

#### 4.2 *Albizia procera*: Immunomodulation and Structural Repair

Parallel research on the ethanolic bark extract of *Albizia procera* (ETBE) by Sangeetha et al. reported similar outcomes in arthritic rats.

- **Mechanism:** ETBE demonstrated a robust anti-inflammatory effect, significantly reducing serum levels of TNF- $\alpha$ , IL-1 $\beta$ , and IL-6, while upregulating the anti-inflammatory cytokine IL-10.<sup>17</sup>
- **Histology:** Like *Leucas*, the study describes "complete cartilage regeneration" characterized by a smooth articular surface and reduced synovial hyperplasia.<sup>17</sup>

#### 4.3 Scientific Critique: Regeneration vs. Repair

While the biochemical data (antioxidant/cytokine levels) in these studies is robust, the histological claim of "complete regeneration" warrants critical skepticism.

- **Spontaneous Repair limitations:** In adult mammals, full-thickness cartilage defects do not spontaneously regenerate into **hyaline cartilage**. Instead, the body typically repairs these defects with **fibrocartilage**, a mechanically inferior tissue composed primarily of Type I collagen rather than Type II.
- **Methodological Ambiguity:** The snippets describing these studies refer to standard histopathological studies (H&E).<sup>15</sup> There is no explicit mention of **polarized light microscopy** or **Type II collagen immunohistochemistry** in these specific *Leucas* and *Albizia* papers. Without these specific techniques, distinguishing between true hyaline cartilage (regeneration) and fibrocartilage (scar repair) is impossible.
- **Conclusion:** It is highly probable that the "complete regeneration" described refers to

the macroscopic restoration of joint surface continuity via fibrocartilaginous repair and the resolution of synovial inflammation, rather than the true restitution of the hyaline articular architecture.

---

## 5. Methodology in Cartilage Research: The Imperative of Polarized Light Microscopy

To accurately assess the validity of the regenerative claims made for these herbal formulations, one must evaluate the imaging modalities employed. The distinction between hyaline cartilage and fibrocartilage is the definitive metric of success in regenerative orthopedics.

### 5.1 The Limitations of Standard Staining

Most studies reviewed (specifically Peedanil Gold, Leucas aspera, Albizia procera) relied on **Hematoxylin & Eosin (H&E)** or **Safranin-O** staining.<sup>1</sup>

- **Safranin-O:** This stain binds to proteoglycans. A positive red stain indicates that the cells in the repair tissue are chondrocyte-like and producing a matrix. However, it does not provide information on the collagen fiber architecture.
- **H&E:** This provides excellent cellular detail (chondrocyte cloning, cellularity) but cannot differentiate collagen types.

### 5.2 The Gold Standard: Polarized Light Microscopy (PLM)

Collagen fibrils possess the optical property of **birefringence**—they refract light differently depending on their orientation.

- **Hyaline Cartilage Signature:** Under polarized light, normal hyaline cartilage displays a complex, highly organized "arcade" structure: vertical fibers in the deep zone, random/oblique fibers in the middle zone, and tangential fibers in the superficial zone.<sup>19</sup> This organization is critical for load-bearing.
- **Fibrocartilage Signature:** Repair tissue (fibrocartilage) typically appears disorganized or displays a uniform birefringence that lacks the zonal stratification of native cartilage.
- **PLM Scoring:** Validated scoring systems (e.g., scale of 0–5) use PLM to quantify the quality of repair. A score of 5 indicates organization identical to native cartilage, while lower scores indicate disorganization.<sup>20</sup>

### 5.3 Assessment of Reviewed Studies

A review of the available methodologies reveals a significant gap:

- **Peedanil Gold / Leucas / Albizia:** These studies relied on brightfield microscopy.<sup>1</sup> Consequently, the claims of "regeneration" must be interpreted with caution. The tissue



observed is likely proteoglycan-rich repair tissue, but its biomechanical equivalence to native cartilage remains unproven without PLM data.

- **Maxing Yigan Formula:** Recent studies on this formulation used the **ICRS (International Cartilage Repair Society)** visual histological score.<sup>22</sup> The ICRS score is a rigorous semi-quantitative metric that often incorporates PLM or specific collagen architecture assessments, lending higher credibility to the regeneration claims associated with the MYF collagen sponge scaffold.

---

## 6. *Caryota mitis*: Dual-Action Pharmacology for Gout and Osteoarthritis

The fruit peel of *Caryota mitis* (Cluster Fishtail Palm) offers a distinct pharmacological profile relevant to metabolic arthritis (gout) and degenerative arthritis (OA).

### 6.1 Xanthine Oxidase Inhibition (Gout)

Gout is driven by the crystallization of uric acid in joints. Uric acid is the end-product of purine metabolism, catalyzed by the enzyme **xanthine oxidase (XO)**.

- **Findings:** Extracts of *Caryota mitis* fruit peel demonstrated significant in vitro inhibition of xanthine oxidase.<sup>24</sup>
- **Active Constituents:** Bioassay-guided fractionation identified **emodin** and **esculetin** (isolated from the CMEA fraction) as the primary compounds responsible for this inhibition.<sup>25</sup> By inhibiting XO, *Caryota mitis* mimics the mechanism of allopurinol, lowering serum uric acid levels and preventing crystal-induced synovitis.

### 6.2 Chondrocyte Proliferation (OA)

Beyond gout, the extract exhibits direct effects on cartilage cellularity.

- **Proliferation:** In vitro assays using young human chondrocytes showed that *Caryota mitis* extracts significantly stimulated cell proliferation.<sup>25</sup> In the context of OA, where chondrocyte senescence and apoptosis lead to matrix failure, an agent that promotes proliferation offers potential disease-modifying activity.
- **Immunomodulation:** The extract also inhibited ROS production, further protecting the proliferating chondrocytes from oxidative stress.<sup>25</sup>

---

## 7. Maxing Yigan Formula: Autophagy Regulation via Tissue Engineering

The Maxing Yigan Formula (MYF), a classical TCM prescription traditionally used for



respiratory dampness, has been repurposed for cartilage tissue engineering. The formula typically comprises **Ephedra** (*Ma Huang*), **Apricot Kernel** (*Xing Ren*), **Coix Seed** (*Yi Yi Ren*), and **Licorice** (*Gan Cao*).<sup>27</sup>

## 7.1 MYF-Incorporated Collagen Sponge (MYF@CS)

To overcome the poor bioavailability of oral TCM administration for joint repair, recent research (Zhang et al., 2024) developed a **MYF-incorporated collagen sponge (MYF@CS)**. This biodegradable scaffold is implanted directly into cartilage defects, serving as a reservoir for the sustained release of MYF bioactive components.<sup>22</sup>

## 7.2 Mechanism: The Autophagy-Senescence Link

The study identified **autophagy** as the central mechanism of MYF's efficacy.

- **Pathology:** In OA, chondrocytes enter a state of senescence where autophagy (the cellular "recycling" process) is downregulated. This leads to the accumulation of damaged mitochondria and proteins, triggering cell death.
- **Therapeutic Action:** MYF was shown to significantly upregulate autophagy in OA chondrocytes.<sup>23</sup> By restoring autophagic flux, MYF clears cellular debris, delays senescence, and maintains the chondrogenic phenotype.
- **Outcome:** In vivo implantation of MYF@CS resulted in superior ICRS scores compared to control scaffolds, indicating enhanced macroscopic and histological repair quality.<sup>22</sup>

---

## 8. Synthesis of Scientific Validity

Based on the evidence reviewed, the scientific validity of these formulations can be stratified as follows:

1. **High Validity (Molecular Mechanism): Osteoking** is supported by the most sophisticated mechanistic data. The elucidation of the ZBP1-STAT1-PKR-MLKL axis provides a cutting-edge explanation for its activity in bone defects, moving beyond vague descriptions of "healing" to specific kinase inhibition.
2. **Moderate Validity (Biochemical/Functional): Peedanil Gold** and **Caryota mitis** are supported by solid biochemical markers (COMP, XO inhibition) and functional recovery data. However, Peedanil Gold requires more rigorous histological validation (PLM) to confirm the "regeneration" claim.
3. **Emerging Validity (Tissue Engineering): Maxing Yigan Formula** represents a high-tech application of TCM. The use of collagen sponges and ICRS scoring lends it significant credibility in the regenerative medicine sphere.
4. **Lower Validity (Histological Interpretation):** The claims of "complete regeneration" for **Leucas aspera** and **Albizia procera** are currently the most scientifically tenuous. While their anti-inflammatory potency is well-documented, the assertion of restoring hyaline cartilage lacks the necessary confirmation via polarized light microscopy or collagen

typing, suggesting an over-interpretation of fibrocartilaginous repair.

---

## 9. Comprehensive Toxicological Analysis and Geriatric Pharmacovigilance

The integration of these herbal formulations into the therapeutic regimen of older adults necessitates a rigorous safety assessment. The geriatric population is characterized by polypharmacy, reduced renal/hepatic clearance, and increased sensitivity to anticholinergic and cardiovascular insults.

### 9.1 The *Datura* Factor: Anticholinergic Burden

**Osteoking** contains *Datura metel* (Yangjinhua).<sup>12</sup>

- **Pharmacology:** *Datura* species are rich in tropane alkaloids, specifically **scopolamine**, **hyoscyamine**, and **atropine**.<sup>30</sup> These are potent competitive antagonists at muscarinic acetylcholine receptors.
- **Geriatric Risk:** Older adults are exquisitely sensitive to anticholinergic toxicity. The "Anticholinergic Burden" is a cumulative risk factor strongly linked to **dementia**, acute delirium, cognitive decline, urinary retention (precipitating crises in benign prostatic hyperplasia), and severe constipation.<sup>32</sup>
- **Conclusion:** The presence of *Datura* makes Osteoking high-risk for any patient with cognitive impairment or those taking other anticholinergic drugs (e.g., oxybutynin, amitriptyline).

### 9.2 The *Ephedra* Factor: Sympathomimetic Toxicity

**Maxing Yigan Formula** contains *Herba Ephedrae* (Ma Huang).<sup>27</sup>

- **Pharmacology:** Contains **ephedrine** and **pseudoephedrine**, which are direct and indirect agonists of alpha- and beta-adrenergic receptors.
- **Geriatric Risk:** Ephedra causes dose-dependent increases in blood pressure and heart rate. It is associated with myocardial infarction, stroke, and arrhythmias.<sup>34</sup>
- **Interactions:** It poses a severe risk when combined with **Beta-blockers**. Non-selective beta-blockers (e.g., Propranolol) block beta-receptor mediated vasodilation, leaving Ephedra's alpha-adrenergic vasoconstriction unopposed, leading to hypertensive crisis.<sup>36</sup>

### 9.3 The *Licorice* Factor: Pseudoaldosteronism

**Maxing Yigan Formula** contains *Glycyrrhiza* (Licorice).<sup>27</sup>

- **Pharmacology:** The active constituent, **glycyrrhizin**, inhibits the enzyme 11 $\beta$ -hydroxysteroid dehydrogenase type 2. This prevents the breakdown of cortisol, allowing cortisol to aberrantly activate mineralocorticoid receptors in the kidney.

- **Geriatric Risk:** This mimics hyperaldosteronism, causing sodium retention, hypertension, and **hypokalemia** (potassium loss).<sup>37</sup>
- **Interactions:** It directly antagonizes the effects of **ACE Inhibitors** (e.g., Lisinopril) and diuretics. Hypokalemia induced by licorice dramatically increases the risk of **Digoxin toxicity** (arrhythmias).<sup>37</sup>

## 9.4 Anticoagulant Interactions: Hemorrhagic Risk

Several ingredients possess potent antiplatelet or anticoagulant properties, posing risks for patients on **Warfarin**, **Clopidogrel**, or **Aspirin**.

- **Panax notoginseng (Osteoking):** Contains saponins (PNS). While some data suggests PNS might induce CYP2C9 (lowering Warfarin levels)<sup>39</sup>, *Panax* has intrinsic antiplatelet activity. Concurrent use with Warfarin or Aspirin increases the risk of bruising and bleeding regardless of INR stability.<sup>40</sup>
- **Carthamus tinctorius (Osteoking):** Safflower extract inhibits platelet aggregation and thrombosis. When combined with anticoagulants, it synergistically prolongs bleeding time.<sup>41</sup>
- **Boswellia serrata (Peedanil Gold):** Studies suggest *Boswellia* may inhibit CYP enzymes (CYP2C9, CYP3A4). Since Warfarin is metabolized by CYP2C9, *Boswellia* could decrease its clearance, elevating INR and bleeding risk.<sup>44</sup>

## 9.5 Heavy Metal Toxicity in Herbo-Mineral Formulations

**Peedanil Gold** is a herbo-mineral formulation. Ayurvedic preparations (*Bhasmas*) utilize calcined minerals.

- **Risk:** Improperly prepared *Bhasmas* can contain toxic levels of **lead**, **mercury**, and **arsenic**. Lead poisoning in the elderly can present vaguely as hypertension, renal insufficiency, or cognitive decline, often misdiagnosed as aging.<sup>45</sup> While reputable manufacturers perform UHPLC/ICP-MS testing<sup>1</sup>, the inherent risk remains a consideration for chronic dosing.

---

# 10. Herb-Drug Interaction Matrix

The following table synthesizes the potential interactions between the discussed herbal ingredients and common geriatric pharmacotherapies.

**Table 1: Safety and Interaction Profile for Geriatric Pharmacotherapy**

Herbal Constituent	Anticoagulants (Warfarin)	Antiplatelets (Aspirin,	Antihypertensives (ACE	Antidiabetics (Metformin)	Statins (Atorvastatin,	Anticholinergics / CNS
--------------------	---------------------------	-------------------------	------------------------	---------------------------	------------------------	------------------------

(Formula tion)	n, Apixaba n)	Clopidog rel)	Inhibitor s, Beta-blo ckers)	min, Insulin)	Simvasta tin)	Agents
<b>Datura metel</b> (Osteokin g)	<b>LOW RISK</b>	<b>LOW RISK</b>	<b>MODER ATE RISK.</b> Tachycar dia may oppose Beta-blo cker efficacy.	<b>LOW RISK</b>	<b>LOW RISK</b>	<b>SEVERE RISK.</b> Additive anticholin ergic burden. High risk of delirium, urinary retention, and dementia .
<b>Ephedra / Ma Huang</b> (Maxing Yigan)	<b>LOW RISK</b>	<b>LOW RISK</b>	<b>SEVERE RISK.</b> Causes hyperten sion. Unoppo sed alpha-ag onism with non-sele ctive Beta-blo ckers (Hyperte nsive Crisis).	<b>MODER ATE RISK.</b> Sympath omimetic effects may acutely raise blood glucose.	<b>MODER ATE RISK.</b> Potential metaboli c interactio n.	<b>MODER ATE RISK.</b> CNS stimulant. Risk with sedatives /antidepr essants.
<b>Glycyrrh iza / Licorice</b>	<b>MODER ATE RISK.</b>	<b>LOW RISK</b>	<b>SEVERE RISK.</b> Causes	<b>LOW RISK</b>	<b>LOW RISK</b>	<b>MODER ATE RISK.</b>

(Maxing Yigan)	May alter metabolism.		Na <sup>+</sup> retention & Hypokalemia. Antagonizes ACE Inhibitors & Diuretics.			Hypokalemia potentiates Digoxin toxicity.
<b>Carthamus / Safflower</b> (Osteokin g)	<b>HIGH RISK.</b> Potentiates anticoagulant effect. Increases bleeding time.	<b>HIGH RISK.</b> Synergistic antiplatelet activity. High bleeding risk.	<b>LOW RISK</b>	<b>LOW RISK</b>	<b>LOW RISK</b>	<b>LOW RISK</b>
<b>Panax notoginseng</b> (Osteokin g)	<b>HIGH RISK.</b> Pharmacodynamic synergism (bleeding) + Pharmacokinetic antagonism (CYP induction). Unpredictable INR.	<b>HIGH RISK.</b> Additive antiplatelet effects.	<b>MODERATE RISK.</b> Can alter vascular tone.	<b>MODERATE RISK.</b> Saponins have hypoglycemic activity; additive effect.	<b>MODERATE RISK.</b> CYP pathway modulation.	<b>LOW RISK</b>
<b>Boswellia serrata</b>	<b>HIGH RISK.</b>	<b>MODERATE</b>	<b>MODERATE</b>	<b>LOW RISK</b>	<b>MODERATE</b>	<b>LOW RISK</b>

(Peedanil Gold)	CYP2C9 inhibition may increase Warfarin levels (High INR).	<b>RISK.</b> Mild antiplatelet effects.	<b>RISK.</b>		<b>RISK.</b> CYP3A4 inhibition may alter statin clearance.	
<b>Curcuma longa</b> (Peedanil Gold)	<b>MODERATE RISK.</b> Mild anticoagulant properties.	<b>MODERATE RISK.</b> Additive antiplatelet risk.	<b>LOW RISK</b>	<b>MODERATE RISK.</b> Synergistic with Metformin/Glyburide. Risk of <b>Hypoglycemia</b> .	<b>LOW RISK</b>	<b>LOW RISK</b>
<b>Caryota mitis</b> (Fruit Peel)	<b>UNCERTAIN.</b> XO inhibitors (like Allopurinol) interact with Azathioprine/Warfarin. Use caution.	<b>UNCERTAIN.</b>	<b>UNCERTAIN.</b>	<b>UNCERTAIN.</b>	<b>UNCERTAIN.</b>	<b>LOW RISK</b>

## 11. Conclusion

The landscape of phytotherapeutic intervention for cartilage regeneration is evolving rapidly, shifting from empirical folklore to molecularly defined pharmacology. **Osteoking** stands out as a formulation with a sophisticated mechanism of action, targeting the ZBP1–STAT1–PKR–MLKL necroptosis pathway to preserve bone and cartilage viability in critical defects. **Peedanil Gold** demonstrates robust efficacy in symptom management and

cytokine suppression comparable to NSAIDs, though its regenerative claims require more rigorous microscopic validation. The **Maxing Yigan Formula** exemplifies the modernization of TCM, utilizing tissue engineering scaffolds to modulate chondrocyte autophagy.

However, the "complete regeneration" claims associated with **Leucas aspera** and **Albizia procera** must be viewed with scientific caution due to the absence of polarized light microscopy in verifying the hyaline nature of the repair tissue.

Most critically, the safety profile of these agents in the geriatric population is complex. The presence of **Datura** (anticholinergic), **Ephedra** (hypertensive), and **Licorice** (hypokalemic) in these formulations creates significant contraindications for elderly patients managing cardiovascular disease, dementia, or renal insufficiency. Clinical translation of these regenerative benefits requires not only standardized extracts but also a vigilant approach to pharmacovigilance, strictly monitoring for hemorrhagic events, hypertensive crises, and cognitive decline in polymedicated seniors.

## Works cited

1. Peedanil Gold, Herbo-Mineral Formulation, Moderates Cytokine Levels and Attenuates Pathophysiology in Monosodium Iodoacetate Induced Osteoarthritis in SD Rat Model - Frontiers, accessed January 8, 2026, <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.883475/full>
2. Peedanil Gold, Herbo-Mineral Formulation, Moderates Cytokine Levels and Attenuates Pathophysiology in Monosodium Iodoacetate Induced Osteoarthritis in SD Rat Model - PMC - NIH, accessed January 8, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9114492/>
3. Peedanil Gold, Herbo-Mineral Formulation, Moderates Cytokine Levels and Attenuates Pathophysiology in Monosodium Iodoacetate Induced Osteoarthritis in SD Rat Model - PubMed, accessed January 8, 2026, <https://pubmed.ncbi.nlm.nih.gov/35600853/>
4. Peedanil Gold, Herbo-Mineral Formulation, Moderates Cytokine Levels and Attenuates Pathophysiology in Monosodium Iodoacetate Induced Osteoarthritis in SD Rat Model - ResearchGate, accessed January 8, 2026, [https://www.researchgate.net/publication/360356558\\_Peedanil\\_Gold\\_Herbo-Mineral\\_Formulation\\_Moderates\\_Cytokine\\_Levels\\_and\\_Attenuates\\_Pathophysiology\\_in\\_Monosodium\\_Iodoacetate\\_Induced\\_Osteoarthritis\\_in\\_SD\\_Rat\\_Model](https://www.researchgate.net/publication/360356558_Peedanil_Gold_Herbo-Mineral_Formulation_Moderates_Cytokine_Levels_and_Attenuates_Pathophysiology_in_Monosodium_Iodoacetate_Induced_Osteoarthritis_in_SD_Rat_Model)
5. Osteoking promotes bone formation and bone defect repair through ZBP1-STAT1-PKR-MLKL-mediated necroptosis - PMC - NIH, accessed January 8, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10797925/>
6. Osteoking promotes bone formation and bone defect repair through ZBP1-STAT1-PKR-MLKL-mediated necroptosis - PubMed, accessed January 8, 2026, <https://pubmed.ncbi.nlm.nih.gov/38238785/>
7. Osteoking promotes bone formation and bone defect repair through ZBP1-STAT1-PKR-MLKL-mediated necroptosis - ResearchGate, accessed



January 8, 2026,

[https://www.researchgate.net/publication/377508587\\_Osteoking\\_promotes\\_bone\\_formation\\_and\\_bone\\_defect\\_repair\\_through\\_ZBP1-STAT1-PKR-MLKL-mediated\\_necroptosis](https://www.researchgate.net/publication/377508587_Osteoking_promotes_bone_formation_and_bone_defect_repair_through_ZBP1-STAT1-PKR-MLKL-mediated_necroptosis)

8. Osteoking Promotes Bone Formation and Bone Defect Repair through ZBP1-STAT1-PKR-MLKL-mediated Necroptosis - ResearchGate, accessed January 8, 2026, [https://www.researchgate.net/publication/376089789\\_Osteoking\\_Promotes\\_Bone\\_Formation\\_and\\_Bone\\_Defect\\_Repair\\_through\\_ZBP1-STAT1-PKR-MLKL-mediated\\_Necroptosis](https://www.researchgate.net/publication/376089789_Osteoking_Promotes_Bone_Formation_and_Bone_Defect_Repair_through_ZBP1-STAT1-PKR-MLKL-mediated_Necroptosis)
9. Osteoking regulates AGEs-RAGE pathway to inhibit ferroptosis and, accessed January 8, 2026, <http://zgswdw.cnjournals.com/zgswjyxxzen/article/html/YX20250583>
10. Osteoking Decelerates Cartilage Degeneration in DMM-Induced Osteoarthritic Mice Model Through TGF- $\beta$ /smad-dependent Manner - PubMed Central, accessed January 8, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8239307/>
11. Osteoking up-regulated the expression of TGF $\beta$ RII and pSmad2 in... - ResearchGate, accessed January 8, 2026, [https://www.researchgate.net/figure/Osteoking-up-regulated-the-expression-of-TGFbRII-and-pSmad2-in-DMM-induced-WT\\_fig3\\_352408773](https://www.researchgate.net/figure/Osteoking-up-regulated-the-expression-of-TGFbRII-and-pSmad2-in-DMM-induced-WT_fig3_352408773)
12. Clinical efficacy of Osteoking in knee osteoarthritis therapy: a prospective, multicenter, non-randomized controlled study in China - Frontiers, accessed January 8, 2026, <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1381936/full>
13. Efficacy and safety of Osteoking on fracture healing: a systematic review and meta-analysis, accessed January 8, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11194365/>
14. Mechanism exploration of Osteoking in the treatment of lumbar disc herniation based on network pharmacology and molecular docking - PubMed Central, accessed January 8, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10809614/>
15. Modulation of inflammatory markers by the ethanolic extract of Leucas aspera in adjuvant arthritis - PubMed, accessed January 8, 2026, <https://pubmed.ncbi.nlm.nih.gov/21251972/>
16. Modulation of inflammatory markers by the ethanolic extract of Leucas aspera in adjuvant arthritis | Request PDF - ResearchGate, accessed January 8, 2026, [https://www.researchgate.net/publication/49771593\\_Modulation\\_of\\_inflammatory\\_markers\\_by\\_the\\_ethanolic\\_extract\\_of\\_Leucas\\_aspera\\_in\\_adjuvant\\_arthritis](https://www.researchgate.net/publication/49771593_Modulation_of_inflammatory_markers_by_the_ethanolic_extract_of_Leucas_aspera_in_adjuvant_arthritis)
17. Attenuation of oxidative stress in arthritic rats by ethanolic extract of Albizia procera benth bark through modulation of the expression of inflammatory cytokines - PubMed, accessed January 8, 2026, <https://pubmed.ncbi.nlm.nih.gov/31785384/>
18. Role of Inflammatory MarNers in Arthritic Rats Treated with Ethanolic BarN Extract of Albizia procera - Zenodo, accessed January 8, 2026, <https://zenodo.org/record/1126313/files/10005304.pdf>

19. The collagenous architecture of articular cartilage. Correlation of scanning electron microscopy and polarized light microscopy observations - PubMed, accessed January 8, 2026, <https://pubmed.ncbi.nlm.nih.gov/455843/>
20. A polarized light microscopy method for accurate and reliable grading of collagen organization in cartilage repair - PubMed, accessed January 8, 2026, <https://pubmed.ncbi.nlm.nih.gov/20955805/>
21. A polarized light microscopy method for accurate and reliable grading of collagen organization in cartilage repair. | Research Bank - Mad Barn, accessed January 8, 2026, <https://madbarn.com/research/a-polarized-light-microscopy-method-for-accurate-and-reliable-grading-of-collagen-organization-in-cartilage-repair/>
22. Guangping Zheng's research works | Nanchang University and other places - ResearchGate, accessed January 8, 2026, <https://www.researchgate.net/scientific-contributions/Guangping-Zheng-2260479246>
23. Maxing Yigan formula promotes cartilage regeneration by regulating chondrocyte autophagy in osteoarthritis - PubMed, accessed January 8, 2026, <https://pubmed.ncbi.nlm.nih.gov/39718676/>
24. Ethnopharmacological and scientific validation of Caryota mitis Lour fruit peel for osteoarthritis and gout management | Request PDF - ResearchGate, accessed January 8, 2026, [https://www.researchgate.net/publication/395077989\\_Ethnopharmacological\\_and\\_scientific\\_validation\\_of\\_Caryota\\_mitis\\_Lour\\_fruit\\_peel\\_for\\_osteoarthritis\\_and\\_gout\\_management](https://www.researchgate.net/publication/395077989_Ethnopharmacological_and_scientific_validation_of_Caryota_mitis_Lour_fruit_peel_for_osteoarthritis_and_gout_management)
25. Ethnopharmacological and scientific validation of Caryota mitis Lour fruit peel for osteoarthritis and gout management - PubMed, accessed January 8, 2026, <https://pubmed.ncbi.nlm.nih.gov/40436126/>
26. New cerebroside and chondrocyte proliferation activity of Caryota mitis L - PubMed, accessed January 8, 2026, <https://pubmed.ncbi.nlm.nih.gov/28906146/>
27. Herbal plants coordinate COVID-19 in multiple dimensions - An insight analysis for clinically applied remedies, accessed January 8, 2026, <https://www.medsci.org/v17p3125.htm>
28. Effectiveness and safety of Maxing Shigan Decoction for community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials - Frontiers, accessed January 8, 2026, <https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1639027/full>
29. Maxing Yigan formula promotes cartilage regeneration by regulating chondrocyte autophagy in osteoarthritis - ResearchGate, accessed January 8, 2026, [https://www.researchgate.net/publication/387376020\\_Maxing\\_Yigan\\_formula\\_promotes\\_cartilage\\_regeneration\\_by\\_regulating\\_chondrocyte\\_autophagy\\_in\\_osteoarthritis](https://www.researchgate.net/publication/387376020_Maxing_Yigan_formula_promotes_cartilage_regeneration_by_regulating_chondrocyte_autophagy_in_osteoarthritis)
30. Anticholinergic Syndrome Due to the Use of Datura Stramonium Seeds for Constipation: A Story of Prolonged ICU Stay - ResearchGate, accessed January 8, 2026,

[https://www.researchgate.net/publication/356198632\\_Anticholinergic\\_Syndrome\\_Due\\_to\\_the\\_Use\\_of\\_Datura\\_Stramonium\\_Seeds\\_for\\_Constipation\\_A\\_Story\\_of\\_Prolonged\\_ICU\\_Stay/download](https://www.researchgate.net/publication/356198632_Anticholinergic_Syndrome_Due_to_the_Use_of_Datura_Stramonium_Seeds_for_Constipation_A_Story_of_Prolonged_ICU_Stay/download)

31. Beauty of the beast: anticholinergic tropane alkaloids in therapeutics - PMC, accessed January 8, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9478010/>
32. Anticholinergic medication use and dementia: latest evidence and clinical implications, accessed January 8, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5014048/>
33. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study, accessed January 8, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6593623/>
34. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine - PubMed, accessed January 8, 2026, <https://pubmed.ncbi.nlm.nih.gov/11795249/>
35. 7 Supplements You May Want to Avoid If You Have High Blood Pressure - GoodRx, accessed January 8, 2026, <https://www.goodrx.com/conditions/hypertension/medications-supplements-that-can-cause-high-blood-pressure>
36. Ephedrine and propranolol Interactions - Drugs.com, accessed January 8, 2026, <https://www.drugs.com/drug-interactions/ephedrine-with-propranolol-981-0-1956-0.html?professional=1>
37. Bioactive Candy: Effects of Licorice on the Cardiovascular System - MDPI, accessed January 8, 2026, <https://www.mdpi.com/2304-8158/8/10/495>
38. Pseudoaldosteronism due to the concurrent use of two herbal medicines containing glycyrrhizin: interaction of glycyrrhizin with angiotensin-converting enzyme inhibitor - PubMed, accessed January 8, 2026, <https://pubmed.ncbi.nlm.nih.gov/16791400/>
39. Mechanism of Panax notoginseng saponins modulation of miR-214-3p/NR1I3 affecting the pharmacodynamics and pharmacokinetics of warfarin - PMC - NIH, accessed January 8, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11385396/>
40. Panax Notoginseng - Uses, Side Effects, and More - WebMD, accessed January 8, 2026, <https://www.webmd.com/vitamins/ai/ingredientmono-906/panax-notoginseng>
41. Interaction Between Chinese Medicine and Warfarin: Clinical and Research Update - Frontiers, accessed January 8, 2026, <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.751107/full>
42. Effects of safflower injection on the pharmacodynamics and pharmacokinetics of warfarin in rats - PubMed, accessed January 8, 2026, <https://pubmed.ncbi.nlm.nih.gov/28783419/>
43. Interaction between warfarin and Chinese herbal medicines - PMC - NIH, accessed January 8, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4325561/>
44. (PDF) Warfarin Interactions with Medicinal Herbs - ResearchGate, accessed January 8, 2026, [https://www.researchgate.net/publication/265651691\\_Warfarin\\_Interactions\\_with\\_](https://www.researchgate.net/publication/265651691_Warfarin_Interactions_with_)

#### [Medicinal\\_Herbs](#)

45. FDA warns about heavy metal poisoning associated with certain unapproved ayurvedic drug products, accessed January 8, 2026,  
<https://www.fda.gov/drugs/fraudulent-products/fda-warns-about-heavy-metal-poisoning-associated-certain-unapproved-ayurvedic-drug-products>
46. Toxic metals in ayurvedic preparations from a public health lead poisoning cluster investigation - PubMed Central, accessed January 8, 2026,  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6060866/>